Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena Inc (NASDAQ: TRVN) is a clinical-stage biopharmaceutical pioneer developing novel therapies for central nervous system disorders and pain management through advanced GPCR targeting. This page provides investors and industry professionals with a comprehensive repository of Trevena news, including clinical trial updates, regulatory milestones, and research developments.
Access timely updates on Trevena's innovative pipeline, including OLINVYK™ (oliceridine) for acute pain and investigational candidates like TRV045 for neuropathic pain. Track progress across preclinical studies, FDA communications, and strategic partnerships that shape the company's trajectory in neuroscience therapeutics.
Key content includes earnings reports, patent filings, scientific presentations, and analyses of Trevena's biased ligand platform—a Nobel Prize-influenced approach to minimizing opioid-related side effects. All materials are curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Trevena's latest advancements in non-opioid pain management and CNS disorder treatments. Regularly updated to reflect new developments in GPCR-focused drug discovery and clinical-stage biopharma innovation.
Trevena, Inc. (Nasdaq: TRVN) recently announced initial topline data from two real-world studies, VOLITION and ARTEMIS, focusing on their opioid, OLINVYK. In VOLITION, 52.2% of OLINVYK patients were GI complete responders, with over 90% feeling 'alert and calm' post-surgery. Meanwhile, ARTEMIS revealed a 1.6-day reduction in hospital stay (approximately 27%) compared to other IV opioids. The studies involved 203 patients in VOLITION and utilized EMR data from 96 OLINVYK and 457 matched patients in ARTEMIS. Initial results reflect positively on OLINVYK's efficacy in managing postoperative pain, though full respiratory outcome data is expected mid-2023.
Trevena Inc. (Nasdaq: TRVN) announced initial topline data from the OLINVYK studies, VOLITION and ARTEMIS, demonstrating positive gastrointestinal (GI) and cognitive outcomes. In the VOLITION study of 203 patients, the GI complete response rate was 52.2%, surpassing previous Phase 3 data. ARTEMIS indicated a statistically significant 1.6-day reduction in average hospital stay compared to other IV opioids. The company has $38.3 million in cash as of year-end 2022, sufficient to fund operations into Q4 2023. Additionally, two proof-of-concept studies for TRV045, a potential treatment for CNS disorders, are underway, with top-line data expected later this year.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, will release its fourth quarter and full year 2022 financial results on March 30, 2023, before market open. A conference call and webcast will follow at 8:00 a.m. ET, featuring executives including Carrie Bourdow, CEO, and Barry Shin, CFO. Trevena, known for OLINVYK (oliceridine) injection for acute pain management, is also exploring innovative therapies for CNS disorders with investigational drugs like TRV045 for neuropathic pain, TRV250 for migraines, and TRV734 for opioid use disorder. The webcast will be accessible on the company's website.
